Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I promised myself I wouldn't check this week but that did not happen
So under this theory are we in the second ABCD pattern since we started to takeoff? Are we in the B pattern following an A which started around 9/27 at ~.20 pps? If so, the next C to follow should push us over the .30 mark, correct?
I'm back online now too
Certainly seems that way...
Nothing on marketwired
If we all placed a sell order with our brokers for a small amount of our shares above $0.28 could we not coax some upward pressure on the share price?
There's been a 146k ask at $0.28 hanging out there for a couple hours with a bid of just a few thousand at $0.2778. Seems deadlocked
Notice that titan does not state their purpose is to sell the robot in their company statment:
[Quote]Titan Medical Inc. is a Canadian public company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”).
Longtai is a distributor owner yes...I'm sure this was a creative financing measure. We are not in the position to dismiss this option but it seems unusual in the US to have this arrangement for a public company.
In this response to or nurse I was thinking of a finance partner / large shareholder and not about business partner like a distributor. Distributor would not necessarily own a stake in titan.
We will pay them in some form or fashion, since they are providing the distribution service. Our net revenues will be less their fee most likely. At first it makes sense to contract distribution but when we have the resources it should become more cost effective to manage the outbound logistics and sales internally.
I can't say with certitude whether a partnership or autonomous path would yield a higher return. However, I can see the rationale behind hobbling over the finish line to commercialization alone - the prospects for a higher return are greater without third party encumbrances. But, without the capacity to get to the finish line alone, a partnership beats losing the entire investment. Who knows...if they can pull it off alone I say let's get that paper!
Amen. And ISRG is not just bad at customer service with surgeons, they aggravate admin constantly. They do not have many fans in their customer base. And it will be so gratifying to watch them wince when they realize they must start satisfying their customers not just slap them around.
I think a specific number of years is irrelevant - long term is a just protracted horizon. There is no certainty in the market so timeframes depend on how risk tolerant the investor is, and their goals. The bottom line is you rolled the dice which was your choice. You have 0 right to any level of profitability regardless of how many years you've been waiting. Its a high risk stock. If that is not OK, perhaps a money market savings or treasury bill would have been a better investment choice. Those are safer and defined in more rigid timeframes : long term is maturity in 10+ years, less is intermediate and short would be less than 1 year.
Good Lord willing, this will be the case for us all! I own a paltry amount compared to you and stang and many here but at $10 with current price basis (No RS) I won't be able to retire just yet but I will be on a good road to have the option to retire before 50 (I'm 31 now). Go Titan!
Understood. But such is the risk one accepts in investing. Timing stocks or the market is a fools errand for 99.99% of the population, studies repeatedly show that steady, consistent investing in a diverdified portfolio over the long run results in a greater returns than timing, due to high transaction costs and the 50% of the tine you guess wrong. What I'm driving at is no matter your purchase price, if you are a long its more likely you will be rewarded. If you expected a quick and handsome profit, your expectations are not in line with reality. This has been my mantra for the last year.
Hear hear. People often lash out at executives because of their own wealth envy, but there's a good reason for high compensation. If you are upset about this, let's hire a CEO at "working man's" pay like those fools Ben and Jerry did, and see what happens. Just like in their little guilt-ridden social justice experiment, we would have to very quickly do an about face and re hire talent to right the ship at market executive pay. Capitalism is a meritocracy; you get what you pay for, and if you over pay for long its your fault (fowler?). At tgis point I think its safe to say our board is not overpaid. Get off it. If you want titan to fail for sure, start driving away talent from our management team.
Wow I love that architecture, what a beautiful building!
I think the problem with this is we are comparing to the market originator. Now the field is opening up but there's more competition. So I'm skeptical it will be as easy for us to reach the $1k SP mark. But who knows. We are the disruptor though...go titan!
Right now IP is proportionally high % of our book value but as we commence sales that should shrink, while increasing in nominal value. It's hard to valuate IP in the scope of an R&D firm. Analysts placed us around $23M earlier this year with the offerings if i remeber correctly. Obviously we feel titxf is severely undervalued, and we should see the market correct this as the company gains viability in the market. So as for the value of our IP...who knows right now? Hard to say. It's as good as soccer tickets if we never commercialize. If I were going to guess I would tie it to the present value of perpetual cash flows we realize from their existence, with a discount for all the other inputs into that revenue. Could be a fun exercise for someone with more time than I!
Ha that was my thought exactly, as I'm sure was true for many here. I belive reality will smack that down with the RS then the company will still do well. I think in 10+ years there is a good chance we could see 20x capital growth on initial investment.
The only one from that marketing pitch that hospitals really watch is length of stay, because there are diminishing marginal returns the longer a patient stays in a single visit. Also, not listed is avoiding readmission from the same procedure because medicare will not pay. Most of those items are patient care issues and are good for marketing but have no bearing on cost/reimbursement. Infection rate is difficult to tie to something like less incision sites and thus not usually considered. Same for blood loss. Both of those are usually more strongly related to the surgeon and not correlated to other variables. Most payors will not reimburse disposables/reposables, which is 100%of the supplies directly attributable to the use of the robot. I think the biggest sell to administration is a lower cost to operate robot. That in mind, txrc will be a competitor from a cost perspective, despite being an inferior clinical offering. Same with flexdex. If surgeons say they can use those for $800 a procedure, instead of a costly robot, admin would jump all over that. Big cost savings.
This correlates strongly with a specific hospital's managed care contracts. However, based on my experience I think it's safe to generalize that most robotic cases are break-even at best, except cardiac.
Thanks this is very informative. To add, from a Bloomberg generated report:
Also I think the market is always right doesn't mean that the market is always right. It's a statement reflecting the nature of supply and demand - if a stock is underpriced, it won't be for long because people will take notice and buy it up to try and harness that alpha! And same for over-priced..that's to say, the market will always find the equilibrium price of a security eventually.
I think the reason we have not seen a higher jump is because we started with a very low basis. 50% in 2 weeks is still pretty remarkable. Perhaps the fact that our moves are less intense and more graduated signals the end of the volatile/speculative nature of Titan; we're heading towards equilibrium pricing based more on the terms of reality. Slow and steady wins the race.
I'm not clinical but I work in healthcare admin specifically dealing with medical devices. I see detachable end effector which looks to be general lap. And I see a couple robot stapler patents (currently only medtronic endogia is licensed to staple with davinci instruments), but the design is clearly made to fit davinci. It appears to me to be coincidental, not correlated to a verb partnership with titan.
...tumbleweed blows past....
(OK not quite breaking It was published yesterday at 4pm but it's still a mention on a significant site!)
BREAKING! Titan get mention on nasdaq site!!!
http://m.nasdaq.com/article/update-tsx-posts-solid-gains-monday-up-62-points-as-oil-and-gold-prices-rise-cm850640
My hope is Mc is holding the roll out at the French hospital until next week to keep the momentum going. Does anyone know if the next unit is ready to ship across the Atlantic? Flenderson?
SP lacks vision. Fortunately for us ISRG is resting on their laurels with it.
Well said.
I'm the same way. Don't want to tell my wife were doing great then the next day tell her nevermind. I provide updates to her on a "long" basis.
Very encouraging, people are watching!...
"Titan has had an “arduous journey,” wrote Whalebone Advisory’s Jeremy Feffer in a note. The company has had to amend its timeline multiple times—just last year, Titan presented the Sport system to investors, aiming for a 2017 U.S. launch.
“[It] appears that the company is finally on track with the latest timeline for its single-port robotic surgery platform, which is intended for general abdominal, gynecologic, and urologic procedures,” Feffer said."
That's doubtful. I hate to pee in your cheerios there pajama boy but I wouldnt touch gigl with a 10 ft pole. They actually have operations and are running a negative margin, and milking you to pay the bills until they close for good. It's one thing for an R&D to have negative cashflows. It's a whole different story when you have payroll, inventory, taxes etc... that you can't pay on an ongoing basis. Good luck with that one.
But this time it's out there to behold where it never was before (beyond a kiosk at sages)
Look at the caption under the stock photo on this link made me lol
http://www.theotcreporter.com/2017/09/19/titan-medical-otcmktstitxf-inks-deal/
Ha yea that's Titan Pharmaceuticals. Little early to be hitting the whisky.